#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

What It Covers

Neurologist and psychiatrist Gayatri Devi outlines how Alzheimer's disease and related dementias exist on a spectrum rather than as binary diagnoses, how biomarker-guided early detection is reshaping risk stratification, why anti-amyloid monoclonal antibodies like lecanumab and donanemab require personalized slow-titration protocols to reduce ARIA risk, and how multimodal treatment combining hormonal, immunological, and neuromodulatory interventions can stabilize or reverse cognitive decline.

Key Questions Answered

• •APOE4 and Anti-Amyloid Therapy Risk: Patients carrying two copies of the APOE4 allele face the highest risk of amyloid-related imaging abnormalities (ARIA) — brain swelling and hemorrhage — from lecanumab or donanemab, yet are also the patients most likely to benefit. Dr. Devi's slow-titration protocol, starting at 3mg/kg rather than the standard 10mg/kg for lecanumab, reduces ARIA incidence to approximately 4% in her five-year clinical series, compared to dramatically higher rates in standard protocols.
• •Neuroinflammation Precedes Amyloid: The prevailing assumption that amyloid deposition is the first pathological event in Alzheimer's is being revised. Emerging evidence suggests neuroimmunological changes precede amyloid accumulation by years, with amyloid following and tau appearing later. This sequence means anti-inflammatory lifestyle interventions initiated in one's thirties or forties — including aggressive management of viral exposures like herpes zoster and HSV — may interrupt the cascade before plaques form, representing a primary prevention window.
• •Blood-Based Biomarker Limitations: Commercially available Alzheimer's blood tests — including Quest AD Detect, Lumipulse, Precivity, and C2N assays — are validated against amyloid PET scans, not against combined amyloid-plus-tau pathology. Since 25–44% of community-dwelling adults in their seventies to nineties carry amyloid without symptoms, a positive blood test alone is insufficient for diagnosis. Dr. Devi recommends confirming positive blood results with either a tau/amyloid PET scan or lumbar puncture before initiating treatment or delivering a diagnosis.
• •Menopause-Related Cognitive Impairment as Distinct Entity: Women in perimenopause or surgical menopause can develop objective cognitive deficits — word-finding difficulty, short-term memory loss, executive dysfunction — that are clinically indistinguishable from early Alzheimer's disease but are driven by estrogen withdrawal. Estrogen receptors colocalize in the hippocampus and drive synaptic sprouting; their loss disrupts connectivity. Transdermal estrogen (gel or patch) is preferred over oral formulations due to lower stroke and venous clot risk, and cholinesterase inhibitors like donepezil can serve as alternatives when estrogen is contraindicated.
• •Lewy Body Dementia Is Frequently Misdiagnosed: Approximately 40% of Alzheimer's patients eventually develop Lewy body pathology, and 30–40% of Lewy body patients carry Alzheimer's biomarkers, making pure presentations rare. A critical clinical error is treating Lewy body patients with levodopa-carbidopa prescribed for presumed Parkinson's disease, which worsens confusion and can trigger psychosis. A distinguishing clinical sign: rest tremor (pill-rolling) appears in Parkinson's but has not been observed in Lewy body presentations. DAT scans and skin punch biopsies testing for alpha-synuclein in cutaneous nerves aid accurate diagnosis.
• •Dementia Staging by Domain, Not Overall Stage: Assigning a single disease stage to a dementia patient obscures clinically meaningful variation. A patient may be at functional stage zero for communication but stage three or four for memory, and a different stage for visuospatial processing. Identifying which domains are most impaired relative to a patient's baseline intellectual ability — for example, language scores at the 10th percentile in someone with overall ability at the 99th percentile — guides treatment prioritization and predicts near-term functional risk more accurately than composite staging.
• •Multimodal Treatment Can Reverse Pathology: Several patients in Dr. Devi's practice have cleared amyloid and subsequently tested negative for tau on PET imaging following sustained monoclonal antibody treatment combined with lifestyle, hormonal, and neuromodulatory interventions including targeted transcranial magnetic stimulation (TMS). TMS, used off-label since 2008, targets the dorsolateral prefrontal cortex, Broca's area, precuneus, and Wernicke's area using neuronavigation-guided MRI mapping. One patient treated since the aducanumab era has remained cognitively stable for seventeen years following IVIG therapy that rendered her amyloid-negative.